Pirtobrutinib: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
Pirtobrutinib: clinical details
Prescribing considerations
- Treatment should be initiated and supervised by a clinician experienced in anticancer therapy.
- Assess infection and opportunistic-infection risk; consider prophylaxis where clinically appropriate.
- Review bleeding history, anticoagulants, antiplatelets and planned procedures.
- Assess cardiovascular history, particularly previous atrial fibrillation or multiple cardiovascular comorbidities.
- Assess tumour burden and tumour lysis syndrome risk.
- Advise sun protection and surveillance for new or changing skin lesions.
- Review pregnancy potential, contraception, breastfeeding and all interacting products.
Contraindications and cautions
- Hypersensitivity to pirtobrutinib or any excipient.
Monitoring
- Full blood count during treatment as clinically indicated.
- Bilirubin and transaminases at baseline and throughout treatment; monitor more frequently if abnormal.
- Clinical assessment for infection and bleeding.
- Heart rhythm symptoms, with ECG when clinically indicated.
- Skin examination for possible second primary skin malignancy.
- Clinical and biochemical monitoring for tumour lysis syndrome in patients at increased risk.
Clinical pharmacology
Pirtobrutinib is an oral, reversible non-covalent BTK inhibitor active against wild-type BTK and C481-mutated BTK. It is primarily metabolised through CYP3A4, UGT1A8 and UGT1A9 and inhibits CYP2C8, BCRP, P-glycoprotein, CYP2C19 and CYP3A to differing degrees.
Formulation and product differences
- Two strengths of blue film-coated tablet are available; one is arc-triangle shaped and the other round.
- Tablets contain lactose and should not be chewed, crushed or split.
- No special storage conditions are required.
Pirtobrutinib preparations and strengths
Tablet
Route: Oral
Strengths: 50 mg, 100 mg
Pirtobrutinib interactions
Give the cancer team a complete list of prescribed, non-prescribed and complementary products. Important examples include:
Anticoagulants, antiplatelets and NSAIDs
Warfarin, heparins, aspirin, ibuprofen and similar products may add to bleeding risk; the combination requires individual assessment and monitoring.
Strong CYP3A inducers
Rifampicin, carbamazepine and phenytoin can substantially reduce pirtobrutinib exposure and should be avoided where possible.
CYP2C8 substrates
Concentrations of medicines such as repaglinide, pioglitazone, rosiglitazone, selexipag and montelukast may increase.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.